PTAB challenges

Proceedings overview

There is one AIA trial proceeding on file for US Patent 8,782,282. The proceeding, IPR2025-01362, has a status of "Discretionary Denial," meaning institution of the inter partes review was denied. This outcome generally strengthens the patent owner's position, as the patent claims remain unchallenged through this particular IPR. For a defendant, this indicates that an IPR-based defense on the specific grounds raised in this petition would be harder to pursue.

IPR2025-01362 — Ciena Corporation v. K.Mizra LLC

• Type: Inter Partes Review
• Filed: 2025-08-31
• Status: Discretionary Denial. Institution of the inter partes review was denied by the Director of the USPTO.
• Judge panel: The institution decision was made by John A. Squires, Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office. The specific panel of Administrative Patent Judges that would have presided over the trial, had it been instituted, is not publicly available for this discretionary denial. However, PTAB Judge Peter D. Shapiro, James A. Tartal, and Kevin C. Trock are listed as panel judges in other similar IPRs. Andrew L. Nalven is also a PTAB panel judge.
• Petition grounds: The petition challenged claims 1-22 of U.S. Patent No. 8,782,282. The specific prior art and statutory bases (§ 102 / § 103 / § 112) for the challenge are not explicitly detailed in the provided snippets, beyond the Patent Owner's brief mentioning "the prior art references underpinning the single ground under which Petitioner seeks review also do not teach at least one of the claim elements of the '282 patent". The petition reportedly overlapped with a parallel ex parte reexamination, citing the same "Verma" reference.
• Institution decision: Denied on 2026-01-08. The institution was denied after review of discretionary considerations, as indicated in a "Director Discretionary Decision: Deny". The denial was based on factors such as Petitioner Ciena Corporation's substantial delay in filing the petition (over nine months after a parallel district court case for patent infringement was filed in the Northern District of Georgia, referred to as the "NDGA Case"), and the significant risk of substantial overlapping issues between the IPR petition and the parallel district court action. Additionally, the Petitioner failed to submit a Sotera stipulation to limit redundancy and inconsistent rulings. The Director determined that allowing the petition to proceed would be inefficient and risk inconsistent rulings.
• Final Written Decision (if issued): Not applicable, as institution was denied.
• Settlement / termination: The proceeding was terminated on 2026-01-08 due to the discretionary denial of institution.
• Appeal: No Federal Circuit appeal has occurred, as there was no Final Written Decision to appeal. Institution decisions are generally not appealable under the AIA.
• Defensive value: The denial of institution means that claims 1-22 of US8782282 were not subjected to inter partes review in this proceeding. Any assertion of these claims against a defendant is not weakened by this particular IPR. This outcome suggests that relying on an IPR strategy with similar grounds or timing in relation to parallel litigation may face similar discretionary denial challenges.

Strategic summary

All claims (1-22) of US8782282 remain untested by way of an IPR, as the sole IPR petition filed (IPR2025-01362) was denied institution. This denial was a discretionary one by the Director, primarily citing Ciena's delay in filing and the potential for inefficient and inconsistent rulings given parallel district court litigation and a co-pending ex parte reexamination. This means the patent has not been narrowed through IPR.

The estoppel landscape under § 315(e)(2) does not apply to Ciena Corporation (and its privies) for the grounds raised in IPR2025-01362, because institution was denied, and thus no Final Written Decision was issued. Estoppel typically arises when an IPR results in a Final Written Decision. However, the PTAB's discretionary denial, based on factors like the pendency of parallel litigation and delay in filing, suggests that future IPR attempts by Ciena (or those in privy with them) on similar grounds might face similar discretionary hurdles. The Patent Owner, K.Mizra LLC, has shown a pattern of actively defending its patent, including requesting discretionary denial and being involved in parallel district court litigation. It is also notable that Unified Patents filed an ex parte reexamination on the '282 patent, which was instituted on July 8, 2025, finding "substantial new questions of patentability on the challenged claims." This indicates that while IPR was denied, the patent is still undergoing a validity challenge in a different forum.

Recommended next steps

Given that IPR2025-01362 was denied institution, there is no Final Written Decision to link to for claim invalidation. However, the Director's Discretionary Decision (January 8, 2026) and the Order Denying Director Review of Institution Decision (March 2, 2026) are significant documents. The "Director Discretionary Decision: Deny" is listed as a decision document and provides insight into the reasoning for denial.

It is crucial to monitor the progress and outcome of the ex parte reexamination initiated by Unified Patents (institution granted on 2025-07-08). This parallel proceeding directly challenges the patentability of claims in US8782282 and could lead to claim cancellations. The median pendency for ex parte reexaminations is approximately 18.1 months from filing to certificate issue date, suggesting that an outcome could be expected in early 2027.